NCT00732771View on ClinicalTrials.gov

Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

May 31, 2009

Conditions
Primary Hyperaldosteronism
Interventions
DRUG

LCI699

Trial Locations (1)

Unknown

Novartis Investigator Site, France

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00732771 - Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism | Biotech Hunter | Biotech Hunter